Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Shuning Ding"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
Jiayi Wu, Shuning Ding, Lin Lin, Xiaochun Fei, Caijin Lin, Lisa Andriani, Chihwan Goh, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, Hui Wang, Ou Huang, Xiaosong Chen, Jianrong He, Yafen Li, Kunwei Shen, Weiguo Chen, Li Zhu
Cancer Res Treat. 2020;52(3):671-679.   Published online January 28, 2020
DOI: https://doi.org/10.4143/crt.2019.387
AbstractAbstract PDFPubReaderePub
Purpose
This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC).
Materials and Methods
Patients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase–polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test.
Results
The MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926).
Conclusion
RS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.

Citations

Citations to this article as recorded by  
  • Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
    Qianyi Lu, Hanxing Zhou, Jianwei Zhang, Kaping Lee, Limin Chen, Ruoxi Hong, Kuikui Jiang, Fei Xu, Wen Xia, Boyang Cao, Jingmin Zhang, Kang Shao, Peng Sun, Shusen Wang
    The Breast.2024; 76: 103760.     CrossRef
  • A clinicopathologic analysis of 70 patients with mucinous breast carcinoma
    Rupali Sood, Karin Miller, Hua-Ling Tsai, Ashley Cimino-Mathews, Roisin M. Connolly
    Current Problems in Cancer: Case Reports.2024; 15: 100304.     CrossRef
  • Clinicopathological features and prognosis of mucinous breast carcinoma with a micropapillary structure
    Beibei Yang, Menglu Shen, Bo Sun, Jing Zhao, Meng Wang
    Thoracic Cancer.2024; 15(36): 2530.     CrossRef
  • Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States
    Guan-Qiao Li, Jia Yao, Ping Zhou, Dan-Xia Chen, Chen-Lu Lian, Shi-Ping Yang, Cai-Hong Huang, San-Gang Wu
    Clinical Breast Cancer.2022; 22(3): 279.     CrossRef
  • Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients
    Yiwei Tong, Jiahui Huang, Weili Ren, Jing Yu, Xu Zhang, Zheng Wang, Jin Hong, Weiqi Gao, Jiayi Wu, Min Ji, Kunwei Shen, Xiaosong Chen
    European Journal of Medical Research.2022;[Epub]     CrossRef
  • Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
    Peng Qi, Yu Yang, Qian-ming Bai, Tian Xue, Min Ren, Qian-lan Yao, Wen-tao Yang, Xiao-yan Zhou
    Breast Cancer Research and Treatment.2021; 186(2): 327.     CrossRef
  • Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
    Rui Chen, Yun Wang, Taolang Li, Junyuan Lv, Guoli Feng, Na Tan, Jinjing Wang, Xiaoming Cheng
    Oncology Letters.2021;[Epub]     CrossRef
  • 7,659 View
  • 165 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study
Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Kunwei Shen, Li Zhu
Cancer Res Treat. 2020;52(2):552-562.   Published online November 18, 2019
DOI: https://doi.org/10.4143/crt.2019.210
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Despite the rapid growing of cancer survivors, prior cancer history is a commonly adopted exclusion criterion. Whether prior cancer will impact the survival of patients with advanced breast cancer (ABC) remains uncertain.
Materials and Methods
Patients with ABC diagnosed between 2004 and 2010 were identified using Surveillance, Epidemiology, and End Results (SEER) database. Timing, stage, and type were used to characterize prior cancer. Multivariable analyses using propensity score–adjusted Cox regression and competing risk regression were conducted to evaluate the prognostic effect of prior cancer on overall survival (OS) and breast cancer-specific survival (BCSS).
Results
A total of 14,176 ABC patients were identified, of whom 10.5% carried a prior cancer history. The most common type of prior cancer was female genital cancer (32.4%); more than half (51.7%) were diagnosed at localized stage; most were diagnosed more than 5 years (42.9%) or less than 1 year (28.3%) prior to the index cancer. In multivariate analyses, patients with prior cancer presented a slightly worse OS (hazard ratio, 1.18; 95% confidence interval [CI], 1.07 to 1.30; p=0.001) but a better BCSS (subdistribution hazard ratio, 0.64; 95% CI, 0.56 to 0.74; p < 0.001). In subset analyses, no survival detriment was observed in patients with prior malignancy from head and neck or endocrine system, at in situ or localized stage, or diagnosed more than 4 years.
Conclusion
Prior cancer provides an inferior OS but a superior BCSS for patients with ABC. It does not affect the survival adversely in some subgroups and these patients should not be excluded from clinical trials.

Citations

Citations to this article as recorded by  
  • Impact of childhood/adolescent cancer history on prognosis in parotid mucoepidermoid carcinoma
    Hefeng Gu, Sunyi Tu, Lan Ma, Kuiwei Su, Yeqing Zhou
    British Journal of Oral and Maxillofacial Surgery.2024; 62(7): 612.     CrossRef
  • Medical history of thyroid cancer does not impair prognosis in non-metastatic breast cancer patients: an analysis study based on SEER database and external cohort
    Shuai Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer
    Chaojie Xu, Dongchen Pei, Yi Liu, Jianhua Guo, Nan Liu, Qian Wang, Yang Yu, Zhengjun Kang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Gallbladder Cancer: A Propensity Score–Adjusted, Population-Based Study
    Jing Wang, Chan Zhang, Dong Yan
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Second primary malignancies in oral tongue cancer: A Surveillance, Epidemiology, and End Result–based analysis evaluating the basic characteristics, survival outcomes, and predictive factors
    Zicheng Xu, Jianxing Wang, Hongzhou Cai, Feng Qi, Qing Zou
    Precision Medical Sciences.2022; 11(1): 4.     CrossRef
  • Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
    Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • [Retracted] Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer
    Weixun Lin, Yaokun Chen, Zeqi Ji, Lingzhi Chen, Jinyao Wu, Yexi Chen, Zhiyang Li, Nauman Rahim Khan
    BioMed Research International.2022;[Epub]     CrossRef
  • Association between a prior cancer history and prognosis in adult patients with high‑grade glioma
    Dongjie He, Peiwen Wu, Gaiyan Li, Siying Zhu, Qiming Wang, Qiuju Shao, Hao Chang
    Journal of Clinical Neuroscience.2022; 106: 20.     CrossRef
  • Impact of prior cancer history on survival of patients with gastric cancer
    Li Wen, Kun Yu, Hongjiang Lu, Guansheng Zhong
    European Journal of Surgical Oncology.2021; 47(9): 2286.     CrossRef
  • Effect of prior cancer on survival outcomes for patients with advanced prostate cancer
    Yechen Wu, Xi Chen, Duocheng Qian, Wei Wang, Yiping Zhang, Jinxin Hu, Jun Zhu, Qiang Wu, Tinghu Cao
    BMC Urology.2021;[Epub]     CrossRef
  • Survival of women diagnosed with breast cancer and who have survived a previous cancer
    Sandi L. Pruitt, Hong Zhu, Daniel F. Heitjan, Asal Rahimi, Bhumika Maddineni, Anna Tavakkoli, Ethan A. Halm, David E. Gerber, Danyi Xiong, Caitlin C. Murphy
    Breast Cancer Research and Treatment.2021; 187(3): 853.     CrossRef
  • Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers
    Chelsea Anderson, Deborah K. Mayer, Hazel B. Nichols
    Cancer.2021; 127(15): 2736.     CrossRef
  • Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER
    Fengyuan Lv, Mingliang Cheng, Liang Jiang, Xiaoping Zhao
    Scientific Reports.2021;[Epub]     CrossRef
  • Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database
    Heyan Chen, Lutong Yan, Shengyu Pu, Lizhe Zhu, Huimin Zhang, Can Zhou, Raffaele Palmirotta
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • Risk of breast cancer-related death in women with a prior cancer
    Fei Ji, Ci-Qiu Yang, Xiao-Ling Li, Liu-Lu Zhang, Mei Yang, Jie-Qing Li, Hong-Fei Gao, Teng Zhu, Min-Yi Cheng, Wei-Ping Li, Si-Yan Wu, Ai-Ling Zhong, Kun Wang
    Aging.2020; 12(7): 5894.     CrossRef
  • 8,107 View
  • 178 Download
  • 18 Web of Science
  • 15 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP